Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. It blocks viral entry into host cells while preserving normal immunologic function. The Company is also investigating an intramuscular method of administration of Trogarzo. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy.


TSX:TH - Post by User

Comment by SPCEO1on May 25, 2022 10:54pm
193 Views
Post# 34708083

RE:TaiMed Biologics

RE:TaiMed BiologicsI am not seeing any news being reported yet on Taimed on Bloomberg but volume traded is up considerably. Maybe there is an effort to buy back the US marketing rights to Trogarzo from TH? I suspect not though as it is unlikely they would try to go it alone and it also seems unlikely Taimed would want the US rights back to pair with the European rights to sell to someone else (since  no one else is likely to be that interested in those rights and because TH could sell the rights to market Trogarzo in the US directly to any company that was interested rather than selling them back to Taimed. TH may also want to retain the US rights as they would have a chance to market anything good Taimed yet might come up with that is a follow on to Trogarzo. That is a long way off but it is an option that might have some value at some point.

Maybe they have some news on one of their other drug programs. But I am not seeing it. 

longterm56 wrote: TaiMed is up the maximum of 10% in early Taiwan trading ... anything that might impact THTX?

   -LT


<< Previous
Bullboard Posts
Next >>